Bionano Genomics (BNGO) Hisse Özeti
Bionano Genomics, Inc. iştirakleriyle birlikte Amerika, Avrupa, Orta Doğu, Afrika, Çin, Japonya, Güney Kore, Singapur, Hindistan ve Avustralya'da genom analizi çözümleri sunmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 3/6 |
| Gelecekteki Büyüme | 2/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 3/6 |
| Temettüler | 0/6 |
Ödüller
Risk Analizi
BNGO Community Fair Values
Create NarrativeSee what 33 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Bionano Genomics, Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$1.16 |
| 52 Haftanın En Yüksek Seviyesi | US$5.50 |
| 52 Haftanın En Düşük Seviyesi | US$1.06 |
| Beta | 1.62 |
| 1 Aylık Değişim | -0.85% |
| 3 Aylık Değişim | -0.85% |
| 1 Yıllık Değişim | -64.74% |
| 3 Yıllık Değişim | -99.69% |
| 5 Yıllık Değişim | -99.90% |
| Halka arzdan bu yana değişim | -99.90% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Jun 24
BNGO: Reproductive And Prenatal Genomic Advances Will Drive Future Upside
Analysts have trimmed their Bionano Genomics price target to $5.00 from $5.50, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples. What’s in the News for Bionano Genomics Published data from 13 optical genome mapping (OGM) studies covering 730 samples in reproductive health and prenatal genetics, highlighting use across infertility, assisted reproduction, recurrent pregnancy loss, prenatal diagnosis, and spontaneous abortion, with OGM assessed alongside karyotyping, CNV sequencing, whole exome sequencing, and long read sequencing.
Anlatı Güncellemesi • Jun 08
BNGO: Clinical Genomic Wins Will Drive Future Quality Control Breakthroughs
Analysts have maintained their price target for Bionano Genomics at $4.00, citing minor adjustments to the discount rate, revenue growth assumptions, profit margin outlook, and future P/E inputs that together support keeping the previous valuation level unchanged. What's in the News Researchers at The University of Texas MD Anderson Cancer Center and Johns Hopkins University School of Medicine published a Modern Pathology study reporting that Bionano's optical genome mapping, or OGM, detected genomic abnormalities in 97.8% of T cell acute lymphoblastic leukemia cases, compared with 55% using conventional cytogenetic analysis, and provided additional genomic insights beyond standard methods in about 70% of cases.
Anlatı Güncellemesi • May 25
BNGO: Growing Clinical Use Cases Will Support Future Upside Potential
Analysts have nudged their price target on Bionano Genomics slightly higher to $6.00, citing updated assumptions for discount rate, revenue growth, profit margin and future P/E, which modestly adjust their outlook on the stock. What's in the News The company issued revenue guidance for Q2 2026, targeting US$7.5 million to US$7.8 million in revenue.Recent updates
Anlatı Güncellemesi • Jun 24
BNGO: Reproductive And Prenatal Genomic Advances Will Drive Future Upside
Analysts have trimmed their Bionano Genomics price target to $5.00 from $5.50, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples. What’s in the News for Bionano Genomics Published data from 13 optical genome mapping (OGM) studies covering 730 samples in reproductive health and prenatal genetics, highlighting use across infertility, assisted reproduction, recurrent pregnancy loss, prenatal diagnosis, and spontaneous abortion, with OGM assessed alongside karyotyping, CNV sequencing, whole exome sequencing, and long read sequencing.Anlatı Güncellemesi • Jun 08
BNGO: Clinical Genomic Wins Will Drive Future Quality Control Breakthroughs
Analysts have maintained their price target for Bionano Genomics at $4.00, citing minor adjustments to the discount rate, revenue growth assumptions, profit margin outlook, and future P/E inputs that together support keeping the previous valuation level unchanged. What's in the News Researchers at The University of Texas MD Anderson Cancer Center and Johns Hopkins University School of Medicine published a Modern Pathology study reporting that Bionano's optical genome mapping, or OGM, detected genomic abnormalities in 97.8% of T cell acute lymphoblastic leukemia cases, compared with 55% using conventional cytogenetic analysis, and provided additional genomic insights beyond standard methods in about 70% of cases.Anlatı Güncellemesi • May 25
BNGO: Growing Clinical Use Cases Will Support Future Upside Potential
Analysts have nudged their price target on Bionano Genomics slightly higher to $6.00, citing updated assumptions for discount rate, revenue growth, profit margin and future P/E, which modestly adjust their outlook on the stock. What's in the News The company issued revenue guidance for Q2 2026, targeting US$7.5 million to US$7.8 million in revenue.Anlatı Güncellemesi • May 03
BNGO: Clinical Evidence For Genome Mapping Will Support Long-Term Upside
Analysts have maintained their $6.00 price target for Bionano Genomics, noting only minor adjustments to assumptions for discount rate, revenue growth, profit margin and future P/E that do not materially change their overall view on the stock. What's in the News Bionano Genomics reported that its auditor, BDO LLP, issued an unqualified opinion in the 2025 Form 10-K while expressing doubt about the company’s ability to continue as a going concern, highlighting funding and liquidity risk that equity holders should monitor closely (10-K filing).Anlatı Güncellemesi • Apr 19
BNGO: Gene Editing QC And Hematology Evidence Will Drive Long-Term Upside
Analysts have reduced their price targets for Bionano Genomics, lowering updated fair value estimates to $6.00 from $8.00, alongside slightly lower revenue growth and profit margin assumptions and a marginally reduced future P/E outlook. What's in the News Bionano Genomics published a multicenter study in the American Journal of Hematology showing that optical genome mapping, or OGM, identified pathogenic or likely pathogenic abnormalities in multiple myeloma samples, including cases where traditional methods such as karyotyping, FISH, and NGS had limited success or returned no result (American Journal of Hematology).Anlatı Güncellemesi • Apr 05
BNGO: Future Gene Editing Quality Control Breakthroughs Will Drive Upside Potential
Analysts have cut their price target on Bionano Genomics roughly in half, to around $4.00 from about $8.00, pointing to a higher discount rate, slightly softer revenue growth expectations near 26%, a modestly better profit margin near 16%, and a higher future P/E multiple closer to 8x as key drivers of the reset. What's in the News A multicenter study in the American Journal of Hematology reported that Bionano's optical genome mapping, or OGM, was concordant with traditional methods in multiple myeloma and identified pathogenic or likely pathogenic abnormalities in a large cohort of 211 samples, including cases where standard tests such as karyotyping and FISH did not yield results (American Journal of Hematology).Anlatı Güncellemesi • Mar 22
BNGO: Gene Editing Safety Data Will Support Future Upside Potential
Analysts have adjusted their price target for Bionano Genomics slightly, reflecting updated assumptions around discount rate, profit margin, revenue growth and future P/E. Together, these factors point to a modest recalibration of their valuation outlook in dollar terms.Anlatı Güncellemesi • Mar 07
BNGO: Gene Editing Safety Insights Will Support Long-Term Upside Potential
Analysts have lowered their price target on Bionano Genomics by $2.00 to $5.50, citing updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. These changes collectively point to a more conservative outlook for the shares.Anlatı Güncellemesi • Feb 20
BNGO: Gene Editing Study And Mapping Sensitivity Will Support Future Upside
Analysts have raised their price target for Bionano Genomics to $12.59 from $12.37, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E that reflect a recalibrated risk and earnings profile. What's in the News Bionano Genomics highlighted a peer-reviewed study in Molecular Therapy: Methods & Clinical Development that used optical genome mapping, or OGM, to assess genomic alterations from multiple gene editing approaches, including transposons, lentiviral transduction, and CRISPR-Cas9 locus insertion (Key Developments).Anlatı Güncellemesi • Feb 06
BNGO: Gene Editing QC Study Will Support Long-Term Upside
Analysts have trimmed their price targets for Bionano Genomics, citing slightly higher assumed discount rates and modest tweaks to long term revenue growth, profit margin and future P/E assumptions that leave their fair value estimate broadly unchanged at around $8.00. What's in the News Bionano Genomics highlighted a peer-reviewed study in Molecular Therapy: Methods & Clinical Development that used its optical genome mapping (OGM) technology to detect genomic alterations introduced by transposons, lentiviral transduction and CRISPR-Cas9 locus insertion in human iPSC lines, supporting OGM as a potential tool for genome integrity QC in gene editing workflows (Key Developments).Analiz Makalesi • Jan 30
Market Cool On Bionano Genomics, Inc.'s (NASDAQ:BNGO) Revenues
With a price-to-sales (or "P/S") ratio of 0.5x Bionano Genomics, Inc. ( NASDAQ:BNGO ) may be sending very bullish...Anlatı Güncellemesi • Jan 23
BNGO: Clinical Study And Genome Mapping Progress Will Support Future Upside
Analysts have adjusted their price target on Bionano Genomics slightly, reflecting modest tweaks to assumptions on discount rate, profit margin, and future P/E. These changes keep their fair value estimate broadly unchanged at about $7.50 per share.Anlatı Güncellemesi • Jan 09
BNGO: Leukemia Study And 2025 Revenue Outlook Will Support Long-Term Upside
Analysts have slightly adjusted their price target for Bionano Genomics, citing modest tweaks in assumptions around discount rate, revenue growth, profit margin, and future P/E as the drivers of this update. What's in the News Bionano Genomics issued earnings guidance for the fourth quarter of 2025, with revenue projected in a range of US$7.5 million to US$7.9 million.Anlatı Güncellemesi • Dec 23
BNGO: Study-Driven Revenue Outlook Will Support Stronger Long-Term Upside Potential
Analysts have lowered their fair value estimate for Bionano Genomics from 11.00 dollars to 8.00 dollars. This reflects a higher perceived risk and cost of capital, despite slightly stronger expectations for revenue growth, profitability, and future valuation multiples.Anlatı Güncellemesi • Dec 09
BNGO: Clinical Study Momentum Will Drive Stronger Demand And Upside Through 2025
Analysts have modestly reiterated their outlook on Bionano Genomics, keeping the price target effectively unchanged as incremental tweaks to the discount rate, revenue growth, and margin assumptions suggest a steady, but not markedly altered, risk reward profile. What's in the News Bionano Genomics issued new revenue guidance for fourth quarter 2025, targeting $7.5 million to $7.9 million, while reiterating full year 2025 revenue expectations of $26.0 million to $30.0 million (company guidance filing).Anlatı Güncellemesi • Nov 25
BNGO: Clinical Study Results Will Drive Increased Demand Through 2025
Analysts have lowered their price target for Bionano Genomics from $9.50 to $7.50 per share, citing updated forecasts for valuation and growth. What's in the News Bionano Genomics initiated earnings guidance for the fourth quarter of 2025, projecting revenue between $7.5 million and $7.9 million, and reiterated full-year 2025 revenue guidance of $26.0 million to $30.0 million (company guidance).Analiz Makalesi • Sep 14
A Piece Of The Puzzle Missing From Bionano Genomics, Inc.'s (NASDAQ:BNGO) 28% Share Price Climb
Bionano Genomics, Inc. ( NASDAQ:BNGO ) shareholders would be excited to see that the share price has had a great month...Anlatı Güncellemesi • Aug 15
VIA Software And Optical Genome Mapping Will Improve Laboratory Efficiency
With both the consensus price target and future P/E holding steady, no notable valuation shift is apparent for Bionano Genomics, keeping fair value unchanged at $9.00. What's in the News Peer-reviewed study demonstrated Bionano's optical genome mapping (OGM) detects novel oncogenic structural variants in infant/toddler T-cell acute lymphoblastic leukemia missed by conventional cytogenetics, identifying distinct prognostic subgroups.Analiz Makalesi • Jul 30
Investors Continue Waiting On Sidelines For Bionano Genomics, Inc. (NASDAQ:BNGO)
Bionano Genomics, Inc.'s ( NASDAQ:BNGO ) price-to-sales (or "P/S") ratio of 0.4x might make it look like a strong buy...
Yeni Anlatı • Apr 16
VIA Software And Optical Genome Mapping Will Improve Laboratory Efficiency
Enhancements in customer utilization and lab efficiency are projected to boost consumable sales and revenue growth.Analiz Makalesi • Apr 05
Revenues Working Against Bionano Genomics, Inc.'s (NASDAQ:BNGO) Share Price Following 26% Dive
To the annoyance of some shareholders, Bionano Genomics, Inc. ( NASDAQ:BNGO ) shares are down a considerable 26% in the...Analiz Makalesi • Feb 11
Slammed 62% Bionano Genomics, Inc. (NASDAQ:BNGO) Screens Well Here But There Might Be A Catch
Bionano Genomics, Inc. ( NASDAQ:BNGO ) shareholders that were waiting for something to happen have been dealt a blow...Analiz Makalesi • Dec 17
Bionano Genomics, Inc. (NASDAQ:BNGO) Might Not Be As Mispriced As It Looks
Bionano Genomics, Inc.'s ( NASDAQ:BNGO ) price-to-sales (or "P/S") ratio of 0.7x might make it look like a strong buy...Analiz Makalesi • Aug 29
Many Still Looking Away From Bionano Genomics, Inc. (NASDAQ:BNGO)
Bionano Genomics, Inc.'s ( NASDAQ:BNGO ) price-to-sales (or "P/S") ratio of 1.1x might make it look like a strong buy...Hissedar Getirileri
| BNGO | US Life Sciences | US Pazar | |
|---|---|---|---|
| 7D | -0.9% | 1.9% | 0.8% |
| 1Y | -64.7% | 17.9% | 20.2% |
Getiri vs. Endüstri: BNGO geçen yıl % 17.9 oranında getiri sağlayan US Life Sciences sektörünün gerisinde kaldı.
Getiri vs Piyasa: BNGO geçen yıl % 20.2 oranında getiri sağlayan US Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| BNGO volatility | |
|---|---|
| BNGO Average Weekly Movement | 5.8% |
| Life Sciences Industry Average Movement | 9.0% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
İstikrarlı Hisse Senedi Fiyatı: BNGO son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: BNGO 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 11% dan 6% a düştü.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 2003 | 96 | Al Luderer | bionano.com |
Bionano Genomics, Inc. iştirakleriyle birlikte Amerika, Avrupa, Orta Doğu, Afrika, Çin, Japonya, Güney Kore, Singapur, Hindistan ve Avustralya'da genom analizi çözümleri sunmaktadır. Şirket, nedensel varyantların kolaylaştırılmış ve basit raporlaması için bilgilendirici veri görselleştirmeleri oluşturmak üzere genom laboratuvarlarının bir dizi platformda verileri analiz etmesini ve yorumlamasını sağlayan genom analiz yazılımı sunmaktadır. Ayrıca, genom analizi ve genetik varyasyon ve fonksiyonun anlaşılması için optik genom haritalama yoluyla yapısal varyasyon analizi için numuneden sonuca çözümler olan Saphyr ve Stratys sistemleri; tek moleküllü görüntüleyiciler olan Saphyr ve Stratys cihazları sunmaktadır; DNA doğrusallaştırma için nano kanal dizilerini paketleyen bir sarf malzemesi olan Saphyr Chip; ultra yüksek moleküler ağırlıklı DNA'nın çıkarılması ve etiketlenmesi için reaktifler ve protokoller sağlayan Bionano Hazırlık Kitleri ve DNA etiketleme kitleri; ve nükleik asit moleküllerini izole eden ve saflaştıran iyonik saflaştırma sistemi.
Bionano Genomics, Inc. Temel Bilgiler Özeti
| BNGO temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$13.20m |
| Kazançlar(TTM) | -US$31.60m |
| Gelir(TTM) | US$28.74m |
0.5x
P/S Oranı-0.4x
F/K OranıBNGO aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| BNGO gelir tablosu (TTM) | |
|---|---|
| Gelir | US$28.74m |
| Gelir Maliyeti | US$15.24m |
| Brüt Kâr | US$13.50m |
| Diğer Giderler | US$45.10m |
| Kazançlar | -US$31.60m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -2.75 |
| Brüt Marj | 46.97% |
| Net Kâr Marjı | -109.95% |
| Borç/Özkaynak Oranı | 27.1% |
BNGO uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/07/06 06:52 |
| Gün Sonu Hisse Fiyatı | 2026/07/06 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Bionano Genomics, Inc. 5 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Yi Chen | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |
| Kevin DeGeeter | Oppenheimer & Co. Inc. |